<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Some in vitro studies have identified an antithrombotic effect of <z:chebi fb="5" ids="18154">polysaccharides</z:chebi> from Laminaria japonica, but this activity remains to be confirmed in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>In this study a <z:chebi fb="5" ids="18154">polysaccharide</z:chebi> fraction termed <z:chebi fb="0" ids="53373">PLG</z:chebi> was extracted from L. japonica in the Beibu Gulf in Guangxi, China, and its antithrombotic effects explored in rat models of carotid and <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Its anticoagulation and antiplatelet properties were assessed by measuring the prothrombin time (PT), activated partial thromboplastin time (APTT) and <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced platelet aggregation rate (Agg(max) ) </plain></SENT>
<SENT sid="3" pm="."><plain>Its effects on <z:mp ids='MP_0001914'>bleeding</z:mp> time were measured using the tail transection method </plain></SENT>
<SENT sid="4" pm="."><plain>It was found that pretreatment with an intraperitoneal injection of <z:chebi fb="0" ids="53373">PLG</z:chebi> at 2.5 or 5.0 mg/kg significantly prolonged the occlusion time in the carotid <z:mp ids='MP_0005048'>thrombosis</z:mp> model, and a dose of 5.0 mg/kg reduced the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight in the <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> model </plain></SENT>
<SENT sid="5" pm="."><plain>Pretreatment with <z:chebi fb="0" ids="53373">PLG</z:chebi> (5.0 mg/kg) increased the APTT and decreased the <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced platelet Agg(max)  </plain></SENT>
<SENT sid="6" pm="."><plain>Neither dose of <z:chebi fb="0" ids="53373">PLG</z:chebi> significantly prolonged the <z:mp ids='MP_0001914'>bleeding</z:mp> time compared with the control group </plain></SENT>
<SENT sid="7" pm="."><plain>In an in vitro anticoagulation assay using human plasma, <z:chebi fb="0" ids="53373">PLG</z:chebi> at 57.14, 28.57 and 28.57 μg/mL inhibited APTT and PT in a concentration-dependent manner </plain></SENT>
<SENT sid="8" pm="."><plain>The results show that <z:chebi fb="0" ids="53373">PLG</z:chebi> possesses antithrombotic activity in a rat model, and that it may prove to be clinically useful in humans </plain></SENT>
<SENT sid="9" pm="."><plain>Copyright © 2011 John Wiley &amp; Sons, Ltd </plain></SENT>
</text></document>